ESMO Highlights

Ahmet Sezer, ESMO 2020 – Cemiplimab in Non-small Cell Lung Cancer and the EMPOWER-Lung 1 Trial

It was a pleasure to meet Dr Ahmet Sezer to discuss the clinical development of cemiplimab as a potential treatment for non-small cell lung cancer and key safety and efficacy findings from the EMPOWER- Lung 1 study. The late-breaking abstract, ‘EMPOWER-Lung 1: Phase 3 first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small […]

Dermatological Cancer

Paolo A Ascierto,ESMO 2020 – The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study

Paolo A Ascierto

Editorial board member, Dr Paolo A Ascierto, joins us at the Virtual 2020 ESMO Congress to discuss immunotherapy in BRAF-mutated metastatic melanoma and the major findings from the The SEquential COMBo Immuno and Targeted therapy (SECOMBIT) study. Questions What is the rationale for the combination of targeted and immunotherapy in the treatment of BRAF-mutated metastatic […]

Breast Cancer, Immunotherapy

Leisha A Emens, ESMO 2020 – Overall Survival Analysis from IMpassion 130 in Triple-negative Breast Cancer

Leisha A Emens

Prof. Leisha A Emens joins touchONCOLOGY to discuss the final overall survival analysis of the phase III IMpassion 130 study investigating atezolizumab plus nab-paclitaxel versus placebo plus nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer. Prof. Emens explores what we can learn from these findings, as well as the failure of IMpassion […]

Policy

Ana Carneiro, ESMO 2020 – Disparities in Access to Oncology Clinical Trials in Europe

Ana Carneiro

At the Virtual 2020 ESMO Congress, Ana Carneiro talks about disparities in access to oncology trials from the last decade. The late-breaking abstract ‘Disparities in access to oncology clinical trials in Europe in the period 2009-2019‘ (LBA66) was presented at the Virtual 2020 ESMO Congress, 19–21 September 2020. Questions Prior to this study, what was […]

Genitourinary Cancers

Ajjai Alva, ESMO 2020 – Pembrolizumab plus Chemotherapy as First-line Therapy for Advanced Urothelial Carcinoma: the KEYNOTE-361 trial

Ajjai Alva,

Dr Ajjai Alva discusses the rationale of pembrolizumab in combination with chemotherapy for the treatment of advanced urothelial cancer and findings from the KEYNOTE-361, and future directions for pembrolizumab research. The late-breaking abstract ‘Pembrolizumab (P) combined with chemotherapy (C) vs C alone as first-line (1L) therapy for advanced urothelial carcinoma (UC): KEYNOTE-361’ (LBA23) was presented […]

COVID-19, Supportive Cancer Care

Florence Joly, ESMO 2020 – Impact of the COVID-19 Pandemic on Cancer Treatments and the Psychological Impact on Patients

Florence Joly,

The COVID-19 pandemic has had a direct impact on cancer care. Prof. Florence Joly discusses the challenges and lessons learned when treating patients with cancer during the pandemic and lockdown period. The late-breaking abstract ‘Impact of the COVID-19 pandemic on management of medical cancer treatments and psychological consequence for the patients’ (LBA69) was presented at […]

Dermatological Cancer

Ana Maria Arance Fernandez, ESMO 2020 – Lenvatinib plus Pembrolizumab for Advanced Melanoma: Initial Results of LEAP-004

Ana Maria Arance Fernandez,

touchONCOLOGY meets with Dr Ana Maria Arance Fernandez at ESMO 2020 to discuss findings from the LEAP-004 trial, and the role lenvatinib plus pembrolizumab can play in the treatment of advanced melanoma. The late-breaking abstract ‘Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: initial results of […]

Genitourinary Cancers, Renal Cancer

Yann-Alexandre Vano, ESMO 2020 – Nivolumab and Ipilimumab or VEGFR Tyrosine Kinase Inhibitor in Naive Metastatic Kidney Cancer: The BIONIKK Trial

Yann-Alexandre Vano

Dr Yann-Alexandre Vano joins touchONCOLOGY to discuss the role of personalization of treatment in kidney cancer, and the major findings from the BIONIKK trial investigating nivolumab and ipilimumab as a first-line therapy for patients with kidney cancer. The late-breaking abstract ‘Results from the phase 2 BIOmarker driven trial with Nivolumab (N) and Ipilimumab or VEGFR […]

Breast Cancer

Aditya Bardia, ESMO 2020 – Sacituzumab Govitecan in Metastatic Triple-negative Breast Cancer: the ASCENT Trial

Aditya Bardia,

touchONCOLOGY meets with Dr Aditya Bardia at the Virtual 2020 ESMO Congress to discuss the recently presented data from the ASCENT trial, and the role sacituzumab govitecan may play in the treatment of previously-treated metastatic triple-negative breast cancer. The late-breaking abstract ‘ASCENT: A randomized phase 3 study of sacituzumab govitecan (SG) vs treatment of physician’s […]

FILTER YOUR SEARCH

Speciality: